The early 1990s seem a long, long time ago ... |
This Kat was always fascinated by the IBC pharma law programmes since they were among the first sectoral conferences, concentrating on a specific industry. Editing what were then seen as niche publications, he felt that the proper way to divide interest in registered rights was by trisecting the topic between (i) getting the rights in the first place (filing, office actions), (ii) suing on them (infringements, threats etc) and (iii) performing transactions with them (licensing, securitisation etc). That way, no-one was excluded from benefiting from the journals' contents. Events such as a Pharma Law conference surely wouldn't thrive, since they excluded patent owners and experts in other industries and thus greatly reduced the potential market for potential registrants.
Events subsequently proved that sectoral analysis has ultimately been more successful than the general approach. Each field of technological application has its own issues. Thus the pharma sector has regulatory, moral and environmental issues, as well as prospects for the extension of patent term, that are either specific to it or shared with few other areas, while patent-pooling and the setting of technical standards -- which require such careful treatment in the telecoms sector -- cause scarcely a ripple in the laboratories of product originators and the boardrooms of their generic nemeses. Patent World and Trademark World are now no more than fond memories, but sector-specific conferences gain in popularity and usefulness, as their participants can be sure that the people they meet are, in professional if not linguistic terms, speaking their language. The Biotech and Pharmaceutical Patent Conference is among the best of them.
W. A. Mozart: never played football for England or won the coveted Young IP Lawyer of the Year award |
Further information about this programme, plus registration details, can be obtained by clicking here. Recognising the discerning nature of this blog's readership, the organisers are kindly offering a generous 10% discount to IPKat blog readers who remember to quote the VIP Kat-code FKW82256IPKE when they book.
Biotech and Pharma: the conference that stood the test of time
Reviewed by Jeremy
on
Sunday, December 11, 2011
Rating:
No comments:
All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.
It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.
Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html